Our vision is to improve the lives of those
affected by respiratory diseases and those who
provide care to them.
- - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - -
Last year, we celebrated 100 years of innovation
in the field of aerosol science and inhalation
technology.
PARI is made up of a worldwide network of
companies, each with a specific focus in
developing or improving aerosol therapies. We
dominate the field of liquid drug aerosol
delivery by nebulizer.
PARI products are considered the “Gold Standard”
for new nebulized medications being developed
and used in clinical trials. Pharmaceutical
companies with approved medications using PARI
products include:
AstraZeneca (Pulmicort® Respules)
Sepracor (Xopenex®)
Dey LP (Accuneb® and DuoNeb®)
Genentech (Pulmozyme®)
Novartis (TOBI®)
Currently, PARI products are being used in 15
additional clinical trials in the development of
new nebulized treatments.
|
